ISPC
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
iSpecimen Inc. (ISPC) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (F). The rating has held at D+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B (3.4) | F (0.3) | D (1.2) | F (0.5) | C+ (2.6) | D+ (1.6) |
| 2026-11-05 | B (3.4) | F (0.2) | D (1.2) | F (0.6) | C+ (2.7) | D+ (1.6) |
| 2026-10-29 | B (3.3) | F (0.2) | D (1.2) | D- (0.7) | C+ (2.7) | D+ (1.6) |
| 2026-10-22 | B (3.3) | F (0.2) | D (1.2) | F (0.5) | C+ (2.6) | D+ (1.6) |
| 2026-10-15 | B (3.4) | F (0.2) | D (1.2) | D- (0.7) | C+ (2.6) | D+ (1.6) |